
    
      cross-sectional Population will be selected through convenience sampling. Patients
      sequentially visiting the rheumatology clinic for routine care who are receiving etanercept,
      adalimumab, or infliximab for between 6 and 24 months will be evaluated for eligibility and
      interest in participation. A maximum of 200 patients per treatment will be enrolled.
    
  